Lv5
1442 积分 2023-04-13 加入
Melanoma-associated antigen A4: A cancer/testis antigen as a target for adoptive T-cell receptor T-cell therapy
1小时前
待确认
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
3天前
已完结
New immune cell engagers for cancer immunotherapy
6天前
已完结
CAR-T cell manufacturing: Major process parameters and next-generation strategies
6天前
已完结
Therapy with oncolytic viruses: progress and challenges
12天前
已完结
GPC-3 in Hepatocellular Carcinoma; A Novel Biomarker and Molecular Target
17天前
已完结
CAR T-cell therapies in China: rapid evolution and a bright future
20天前
已完结
CAR T therapy beyond cancer: the evolution of a living drug
20天前
已完结
First-in-class versus best-in-class: an update for new market dynamics
26天前
已完结
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
1个月前
已完结
皖公网安备34019202002308
